Mar 18, 2017

PARP inhibitors: Synthetic lethality in the clinic

Christopher J Lord, Alan Ashworth


PARP inhibitors (PARPi), a cancer therapy targeting poly(ADP-ribose) polymerase, are the first clinically approved drugs designed to exploit synthetic lethality, a genetic concept proposed nearly a century ago. Tumors arising in patients who carry germline mutations in either BRCA1 or BRCA2 are sensitive to PARPi because they have a specific type of DNA repair defect. PARPi also show promising activity in more common cancers that share this repair defect. However, as with other targeted therapies, resistance to PARPi arises in advanced disease. In addition, determining the optimal use of PARPi within drug combination approaches has been challenging. Nevertheless, the preclinical discovery of PARPi synthetic lethality and the route to clinical approval provide interesting lessons for the development of other therapies. Here, we discuss current knowledge of PARP inhibitors and potential ways to maximize their clinical effectiveness.

  • References66
  • Citations126
  • References66
  • Citations126


Mentioned in this Paper

BRCA2 Protein
BRCA1 protein, human
Antineoplastic Agents
Germ-Line Mutation
DNA Repair
Base Excision Repair
PARP1 protein, human

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Breast Cancer: Therapeutic Approaches

Several different therapeutic approaches are used to treat breast cancer. These include chemotherapy, hormonal therapy, targeted therapy, and Immunotherapy. Discover the latest research on breast cancer therapeutic approaches here.

Related Papers

Critical Reviews in Oncology/hematology
Amy DréanAlan Ashworth
Frontiers in Pharmacology
Alicia MontoniGirish M Shah
© 2020 Meta ULC. All rights reserved